Suven Life Sciences Limited (BOM:530239)
India · Delayed Price · Currency is INR 307.10
+7.50 (2.50%)
At close: Jul 31, 2026
Suven Life Sciences Financials Overview
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 71.15 | 71.15 | 66.56 | 116.93 | 135.95 | 119.51 |
Revenue Growth | 6.89% | 6.89% | -43.08% | -13.99% | 13.76% | -15.08% |
Gross Profit Gross Profit Growth | 71.15 | 71.15 | 59.05 | 108.69 | 130.29 | 95.18 |
Operating Income Operating Income Growth | -2,901 | -2,901 | -1,712 | -1,343 | -1,320 | -1,262 |
Net Income Net Income Growth | -2,763 | -2,763 | -1,607 | -1,051 | -1,183 | -1,220 |
Earnings Per Share EPS Growth | -12.13 | -12.13 | -7.37 | -4.82 | -6.63 | -9.05 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
India India Growth | 47.31 | 28.97 | 83.92 | 62.98 |
United States of America (USA) United States of America (USA) Growth | 0.63 | 50.74 | 38.54 | 44.43 |
Europe Europe Growth | 3.49 | 24.39 | 2.04 | 1.39 |
Rest of the World Rest of the World Growth | 15.13 | 12.83 | 10.9 | 9.64 |
Total Total Growth | 66.56 | 116.93 | 135.39 | 118.44 |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 5,218 | 5,218 | 600.05 | 2,399 | 2,284 | 504.36 |
Total Debt Total Debt Growth | 166.94 | 166.94 | - | 7.1 | 16.05 | 32.09 |
Net Cash (Debt) Net Cash Growth | 5,051 | 5,051 | 600.05 | 2,392 | 2,268 | 472.27 |
Net Cash Growth | 741.79% | 741.79% | -74.91% | 5.44% | 380.28% | 13.55% |
Net Cash Per Share Net Cash Per Share Growth | 22.17 | 22.17 | 2.75 | 10.97 | 12.72 | 3.50 |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | -3,018 | -3,018 | -1,541 | -1,155 | -1,160 | -1,275 |
Capital Expenditures CapEx Growth | -50.83 | -50.83 | -372.76 | - | -28.95 | -197.72 |
Free Cash Flow Free Cash Flow Growth | -3,069 | -3,069 | -1,914 | -1,155 | -1,189 | -1,473 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 100.00% | 100.00% | 88.71% | 92.95% | 95.84% | 79.64% |
Operating Margin | -4077.70% | -4077.70% | -2572.07% | -1148.48% | -971.27% | -1056.14% |
Pretax Margin | -3884.13% | -3884.13% | -2415.11% | -907.20% | -869.95% | -1020.82% |
Profit Margin | -3884.13% | -3884.13% | -2415.11% | -898.63% | -869.95% | -1020.82% |
FCF Margin | -4313.18% | -4313.18% | -2875.39% | -987.51% | -874.42% | -1232.64% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 2, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Forward PE | - | 3.65 | 3.65 | 3.65 | 3.65 | 3.65 |
PS Ratio | 1138.33 | 492.44 | 371.55 | 185.94 | 77.75 | 112.83 |